Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9618 posts found.

Experimental stem cell treatment shows promise in rheumatoid arthritis

August 10, 2016 Research and Development Mesoblast, rheumatoid arthritis, stem cell treatment

Mesoblast has announced results from a Phase II clinical trial evaluating MPC-300-IV in patients with biologic refractory rheumatoid arthritis (RA) …
News
takeda_tokyo_hq

Old CDF drug not recommended in initial NICE guidance due to lack of evidence

August 10, 2016 Research and Development, Sales and Marketing Adcetris, Cancer Drugs Fund, NICE, Takeda, hodgkin's lymphoma

The National Institute for Health and Care Excellence (NICE) has published draft guidance not recommending Takeda’s Adectris (brentuximab vedotin), despite …
News
pharma_pill_manufacturing

Helsinn and MEI Pharma join forces to develop leukaemia drug Pracinostat

August 9, 2016 Manufacturing and Production, Research and Development Helsinn, MEI Pharma, Pracinostat, chronic myeloid leukaemia

Swiss pharmaceutical group Helsinn has entered an agreement with MEI Pharma over the licensing, development and commercialisation of Pracinostat (SB939) …
News
ema_inside

New therapy wins EMA orphan drug designation for ALS

August 9, 2016 Manufacturing and Production, Research and Development EMA, Ice Bucket Challenge, ab science, als, masitinib, oprhan drug designation

French pharma company AB Science has announced that the European Medicines Agency has granted orphan drug status to masitinib for …
News
merckincweb2

FDA approves MSD’s Keytruda for head and neck cancer treatment

August 8, 2016 Manufacturing and Production, Research and Development Cancer, FDA, MSD, keytruda

The US Food and Drug Administration (FDA) has approved MSD’s Keytruda (pembrolizumab) for treatment of recurrent or metastatic head and …
News
bms

SMC reverses decision on Opdivo in advanced skin cancer

August 8, 2016 Manufacturing and Production, Research and Development SMC, Scottish Medicines Consortium, melanoma, opdivo, skin cancer

The Scottish Medicines Consortium (SMC) has reversed an earlier decision for Bristol-Myers Squibb’s Opdivo (nivolumab) and has now approved recommended …
News

Apellis Pharmaceuticals appoints Dr Robert Kim as CMO

August 8, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Apellis, CMO, GSK, Novartis, appointment

Clinical stage complement immunotherapy company Apellis Pharmaceuticals has named its new chief medical officer as Dr Robert Kim. Kim’s primary …
Appointment
humira_abbott_

AbbVie files lawsuit against Amgen over Humira copy

August 8, 2016 Research and Development, Sales and Marketing AbbVie, Amgen, FDA, Humira, rheumatoid arthritis

Abbvie has filed a patent infringement lawsuit against Amgen over the latter firm’s copy of its Humira (adalimumab) rheumatoid arthritis …
News
test_results

The power of PrEP

August 8, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, PrEP, high court, lifestyle drug

Many among the general public may not have heard about PrEP, or pre-exposure prophylaxis, before last week when a high …
Feature
4741451457_6344b99835_z_-_copy

‘Game changer’ asthma pill sees significant reduction in severe symptoms

August 8, 2016 Research and Development, Sales and Marketing Fevipiprant, Novartis, asthma, university of Leicester

A study at the University of Leicester has found that Fevipiprant (QAW039), the first new asthma pill for nearly 20 …
News
opdivo_1

Shock for BMS as Opdivo misses goal in late-stage lung cancer trial

August 5, 2016 Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Checkmate, lung cancer, opdivo

Bristol-Myers Squibb has announced that its much heralded cancer therapy, Opdivo (nivolumab), failed to meet its primary endpoint of progression-free …
News
4420456374_64a3d7e6aa

Top ten stories in the pharmaceutical industry this week

August 5, 2016 Medical Communications, Research and Development Actavis, Bioelectronics, CDF, Celgne, EMA, GSK, GlaxoSmithKline, Innovate UK, Medivation, NICE, Novartis, Roche, Sanofi, Teva, appointments, apremilast, biog, breast cancer, brexit, google, pharmaceutical industry, rheumatoid arthritis, sarilumab, top ten

It’s Friday, and we’ve seen some big developments in the industry’s headlines throughout the week, from news of Glaxo-Smith-Kilne’s new …
News

Novo Nordisk diabetes drug Victoza fails to reduce heart failure risk

August 5, 2016 Medical Communications, Research and Development Eli Lily, Novo Nordisk, Victoza, diabetes, heart failure

Novo Nordisk’s diabetes drug Victoza (liraglutide), which was found to cut cardiovascular risks in sufferers of heart disease, has failed …
News

Majority of US patients’ groups supporting pharma against Medicare reforms received industry funding, claims report

August 5, 2016 Medical Communications, Research and Development medicare reform, patients' groups, public citizen

An overwhelming majority of US patients’ groups who supported the pharmaceutical industry in opposing Medicare part B pricing reforms receive …
News
regeneron

Eylea sales jump helps boost Regeneron in Q2 results

August 5, 2016 Medical Communications, Research and Development 2016, Eylea, Q2, Regeneron, results

Regeneron Pharmaceuticals has published positive Q2 results with a 27% rise in Eylea (aflibercept) sales in the US helping to …
News
The Gateway to Local Adoption Series

Latest content

Campaign highlights low expectations among patients with depression

May 7, 2026

Practical AI toolkit launched to help manufacturers cut through complexity

May 6, 2026

Syngene appoints Maninder Kapoor Puri as CHRO

May 6, 2026

BioPhorum acquires PharmaX Solutions

May 5, 2026

Syngene appoints Abhijit Zutshi as CCO

May 5, 2026